Bottom line
IXJ vs GGHCX: the short answer
IXJ (iShares Global Healthcare ETF) and GGHCX (INVESCO Health Care Fund) share a meaningful slice of their top holdings — about 51% by weight.
IXJ is cheaper at 0.38% vs 1.07% — a difference of $69 a year per $10,000 invested.
Over five years, IXJ returned +6.4% a year vs +2.6% for GGHCX.
GGHCX has a front-end sales load of up to 5.5%; the other does not.
Updated Nov 19, 2026
IXJ vs GGHCX side by side
| IXJ | GGHCX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | iShares | Invesco |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.38% | 1.07% |
| Annual cost per $10k | $38 | $107 |
| 10-yr cost on $10k (prospectus) | $480 | $1,784 |
| Max front load | None | 5.5% |
| 12b-1 fee | 0% | 0.25% |
| 1-yr return | +14.9% | +9.2% |
| 5-yr return (annualized) | +6.4% | +2.6% |
| 10-yr return (annualized) | +8.2% | +5.8% |
| Best quarter | +13.6% | +19.6% |
| Worst quarter | −11.8% | −16.5% |
| Net assets (fund) | $3.8B | $1.2B |
| Number of holdings | 124 | 82 |
| Portfolio turnover | 2% | 59% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | IXJ | GGHCX | Difference |
|---|---|---|---|
| 2025 | +14.9% | +15.5% | −0.6% |
| 2024 | +0.6% | +4.0% | −3.4% |
| 2023 | +3.5% | +3.1% | +0.4% |
| 2022 | −4.7% | −13.5% | +8.8% |
| 2021 | +19.5% | +12.2% | +7.3% |
| 2020 | +12.5% | +14.5% | −2.0% |
| 2019 | +23.4% | +32.0% | −8.6% |
| 2018 | +2.9% | +0.5% | +2.4% |
| 2017 | +20.3% | +15.5% | +4.9% |
| 2016 | −6.2% | −11.7% | +5.5% |
Source: Fund prospectus bar charts
Holdings overlap
9 of IXJ's top 25 holdings also appear in GGHCX's top 25.
| Holding | IXJ | GGHCX |
|---|---|---|
| Eli Lilly And Company | 10.93% | 10.59% |
| Johnson & Johnson | 7.04% | 6.76% |
| Abbvie Inc. | 5.12% | 4.03% |
| Unitedhealth Group Incorporated | 4.40% | 6.17% |
| Merck & Co., Inc. | 4.12% | 4.59% |
| Thermo Fisher Scientific Incorporated | 2.42% | 1.55% |
| Gilead Sciences, Inc. | 2.04% | 3.63% |
| Cvs Health Corporation | 1.71% | 2.52% |
| Vertex Pharmaceuticals Incorporated | 1.64% | 2.01% |
Source: SEC Form N-PORT
IXJ top 10
- Eli Lilly And Company — 10.93%
- Johnson & Johnson — 7.04%
- Abbvie Inc. — 5.12%
- Unitedhealth Group Incorporated — 4.40%
- Merck & Co., Inc. — 4.12%
- Astrazeneca Plc — 3.76%
- Roche Holding AG — 3.75%
- Novartis AG — 3.71%
- Amgen Inc. — 2.54%
- Thermo Fisher Scientific Incorporated — 2.42%
GGHCX top 10
- Eli Lilly and Co. — 10.59%
- Johnson & Johnson — 6.76%
- UnitedHealth Group Inc. — 6.17%
- Invesco Private Prime Fund — 4.67%
- Merck & Co., Inc. — 4.59%
- AbbVie Inc. — 4.03%
- Gilead Sciences, Inc. — 3.63%
- argenx SE — 3.24%
- CVS Health Corp. — 2.52%
- Welltower Inc. — 2.34%
FAQ
What is the difference between IXJ and GGHCX?
Which is cheaper, IXJ or GGHCX?
Should I own both IXJ and GGHCX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.